Lantheus Holdings, Inc.

Good morning. Welcome to the Lanthews Third Quarter 2023 Financial Results Conference Call. This is your operator for today's call. Please note that all lines have been placed in mute to prevent any background noise. This call is being recorded for replay purposes. A replay of the webcast will be available in the Investors section of the company's website approximately two hours after the completion of the call. and will be archived for at least 30 days. I will now turn the call over to your host for today, Mark Kinarni, Vice President of Investor Relations. Mark?

Thank you. Good morning and welcome to today's call. With me are Marian Haino, our CEO, Paul Blanchfield, our President, and Bob Marshall, our Chief Financial Officer. Marian will begin the call with introductory remarks and then turn the call over to Paul to provide a strategic and operational update. Bob will cover our financial results and provide updated guidance. Mary Ann will provide closing remarks, and then we will open the call for Q&A. This morning, we issued a press release, which was furnished to the Securities and Exchange Commission under Form 8K, reporting our third quarter 2023 results. The release and today's slide presentation are in the Investors section of our website at lantheus.com. I would like to remind you that any comments made during our call today could include forward-looking statements. Actual results may differ materially from these statements due to a variety of risks and uncertainties. Please note that we assume no obligation to update our commentary or any forward-looking statements except as required by applicable law, even if actual results or future expectations change materially. Please refer to our FCC filings for a detailed discussion of these risks and uncertainties. Discussions during the call will also include certain non-GAAP financial measures. Reconciliation of these measures to the most directly comparable GAAP financial measures is also included on the investor section of our website. It is my pleasure to now turn the call over to our CEO, Marianne.

Thank you, Mark, and good morning to everyone. This was another terrific quarter for Lantheus. We reported revenue of $319.9 million, up 33.7% year over year, and progressed our internal R&D and our business development efforts to expand our pipeline. I am proud to report we have impacted the lives of more than 4.7 million patients year to date. We believe our market-leading position in PSMA imaging and our advancing pipeline, combined with our unique capabilities, will continue to support our position as the leading radiopharmaceutical-focused company. Polarify is the clear market leader in PSMA PET imaging. Growth during the quarter was driven by brand preference for Polarify due to its clinical and commercial value proposition. We believe Polarify offers the best combination with our proprietary PSMA-targeted ligand and the F18 isotope. Turning to the total market opportunity, we estimate the current addressable market for the PSMA PET imaging agents to be 1.6 billion and believe this market potential will grow to more than 3 billion by 2028. As such, we remain encouraged by the current and future growth potential of Polarify. PNT2002, our investigational PSMA-targeted radiotherapeutic asset represents another significant opportunity for growth within our prostate cancer franchise. PNT2002 is designed to treat patients with metastatic castrate-resistant prostate cancer, or MCRPC, who have progressed following treatment with an androgen receptor pathway inhibitor, or ARPI. We are excited about the progress we have made with our partner, Point Biopharma, and look forward to the top-line data from the phase three splash trial in fourth quarter 2023. As we consider the radiopharmaceutical landscape, We view the proposed acquisition of POINT by Eli Lilly as further validation of the opportunity we see for PNT2002 and PNT2003 and the increasing role of radiopharmaceuticals in life sciences. In addition to prostate cancer, we have a number of exciting assets, including PNT2003, our late-stage radiotherapeutic product candidate for neuroendocrine tumors. Another asset is MK6240. our investigational tau imaging agent, intended to assist the diagnosis and staging of Alzheimer's disease patients, which was recently granted fast-track designation by the FDA. And finally, our fibroblast activation protein, or FAP, targeted pet diagnostic imaging agent, is being clinically investigated in multiple tumor types. To supplement our ongoing R&D efforts, we will continue to leverage our significant radiopharmaceutical expertise and resources to target business development opportunities. With that, I'll now turn the call over to Paul.